MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...
Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight
DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...
Science Daily21h
Researchers develop nanofiber patch for treatment of psoriasis
Researchers have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other inflammatory skin diseases.
clinicaladvisor.com18h
Emrosi Approved to Treat Inflammatory Lesions of Rosacea
Emrosi is expected to be available in the first quarter or early second quarter of 2025. The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release capsules) ...
FDA approves Emrosi for rosacea in adults
The U.S. Food and Drug Administration has approved Journey Medical's Emrosi (minocycline hydrochloride) for the treatment of ...